Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
PaperCitations, authors & open-access status
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 478 citations, 2012 year and green oa status.
478
Citations
2012
Year
green
OA Status